Physician profile
Christina Thacker
NPI 1699225730
$1,885.10
in general payments reported to CMS, 2019-2025
18 companies · $583 in 2025
The $583 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.73 · 2022: $32.74 · 2023: $594 · 2024: $612 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.92 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $240.85 | 2022-2025 | Farxiga, Airsupra |
| Corcept Therapeutics | $154.46 | 2024-2025 | Korlym |
| Exeltis, USA INC. | $96.75 | 2024-2025 | Slynd, Twirla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.63 | 2023-2024 | Jardiance |
| Globus Medical, INC. | $69.61 | 2024 | Rise, Base, Modulus |
| Bayer Healthcare Pharmaceuticals INC. | $63.33 | 2023-2024 | |
| Linus Health, INC. | $52.35 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $50.69 | 2021 | |
| Amgen INC. | $49.63 | 2021-2025 | Evenity |
| Pfizer INC. | $41.29 | 2023-2025 | |
| Organon LLC | $37.65 | 2022-2023 | Nexplanon |
| Novo Nordisk INC | $34.61 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $17.60 | 2023 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $16.61 | 2024 | Gvoke Hypopen |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.54 | 2024 | Camzyos |
| Idorsia Pharmaceuticals US INC | $14.73 | 2023 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $13.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Thacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.